Medpace (NASDAQ:MEDP) Now Covered by Barclays

Research analysts at Barclays assumed coverage on shares of Medpace (NASDAQ:MEDP - Get Free Report) in a note issued to investors on Tuesday, MarketBeat.com reports. The firm set an "equal weight" rating and a $300.00 price target on the stock. Barclays's price objective would suggest a potential downside of 3.20% from the company's current price.

Several other equities analysts have also recently issued reports on MEDP. Truist Financial lowered their target price on shares of Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a research note on Wednesday, April 23rd. Mizuho lowered their price objective on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Leerink Partners began coverage on shares of Medpace in a report on Monday, March 24th. They issued a "market perform" rating and a $330.00 target price on the stock. Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a research note on Monday, March 24th. Finally, TD Cowen cut Medpace from a "buy" rating to a "hold" rating and lowered their price target for the company from $370.00 to $328.00 in a report on Monday, April 14th. Twelve investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, Medpace currently has an average rating of "Hold" and a consensus target price of $344.82.

Medpace Price Performance

NASDAQ MEDP traded up $3.11 during mid-day trading on Tuesday, reaching $309.91. The stock had a trading volume of 304,448 shares, compared to its average volume of 371,533. The stock has a market cap of $8.91 billion, a PE ratio of 23.66, a price-to-earnings-growth ratio of 5.61 and a beta of 1.47. Medpace has a 1 year low of $250.05 and a 1 year high of $459.77. The company has a fifty day moving average price of $300.65 and a 200 day moving average price of $320.45.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $3.06 by $0.61. The firm had revenue of $558.57 million during the quarter, compared to analysts' expectations of $528.38 million. Medpace had a return on equity of 54.36% and a net margin of 19.31%. During the same quarter in the previous year, the business earned $3.20 earnings per share. As a group, equities research analysts expect that Medpace will post 12.29 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of the stock in a transaction on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the sale, the director now directly owns 2,998 shares of the company's stock, valued at $904,856.36. This represents a 36.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 20.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Lindbrook Capital LLC grew its position in shares of Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after purchasing an additional 29 shares in the last quarter. HBK Sorce Advisory LLC boosted its position in shares of Medpace by 0.5% during the fourth quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company's stock worth $1,789,000 after acquiring an additional 29 shares during the last quarter. Assetmark Inc. boosted its position in shares of Medpace by 20.1% during the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after acquiring an additional 29 shares during the last quarter. Proficio Capital Partners LLC grew its stake in Medpace by 4.1% during the fourth quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock valued at $243,000 after acquiring an additional 29 shares in the last quarter. Finally, Schulhoff & Co. Inc. increased its holdings in Medpace by 1.2% in the 4th quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company's stock valued at $874,000 after acquiring an additional 30 shares during the last quarter. Institutional investors own 77.98% of the company's stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.